undamentalytics Newsletter

Troendle August J.: insider trades

Chief executive, Director at 2 companies we cover. 10 open-market purchases and 47 sales not made under a pre-set plan, reported from June 16, 2015 to October 1, 2026.

Would copying Troendle August J.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 10 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on July 19, 2022 into $15,211 by November 2, 2026, +10.3% a year. The copy held shares only 18% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $12,628, +5.6% a year (the S&P 500 held throughout made $20,395, +18.1% a year). Beta against the index was 0.42. Twelve months after each report, the average purchase was +51.9% against the S&P 500 (median +49.3%), and 100% beat it. Measured from the trade date, the insider’s own timing, the average was +55.9%. After their sales, the shares moved −25.3% against the index over 12 months on average (a negative figure means selling was the right call); 89% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k 20222023202420252026 $20.4k$15.2k$12.6k
Copying Troendle August J.S&P 500, same days investedS&P 500, held throughout $10,000 copying Troendle August J.’s open-market purchases from July 19, 2022, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+10.3%
S&P 500, same days invested
+5.6% (held throughout +18.1%)
Time in shares
18%
Sharpe ratio (S&P 500)
0.32 (0.84)
Biggest drop (S&P 500)
−27% (−19%)
Market sensitivity (beta)
0.42
Purchases copied
10

Trade by trade

Troendle August J.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 10 +29.3% +33.6% 100% 1 — — Not enough years
Purchases, 6 months after the report 10 +21.2% +16.0% 100% 1 — — Not enough years
Purchases, 12 months after the report 10 +51.9% +49.3% 100% 1 — — Not enough years
Purchases, 12 months after the trade 10 +55.9% +55.0% 100% 1 — — Not enough years
Sales, 3 months after the report 35 −0.7% −6.8% 69% 5 0.80 0.47 No reliable evidence
Sales, 12 months after the report 26 −25.3% −33.2% 89% 4 −1.85 0.16 No reliable evidence
Sales, 12 months after the trade 26 −25.3% −33.3% 89% 4 −1.81 0.17 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Medpace Holdings, Inc. MEDP President & CEO1046July 18, 2022October 1, 2026
Coherus Oncology, Inc. CHRS —01June 16, 2015June 16, 2015

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
October 1, 2026September 29, 2026 MEDP Sale $30,320,929 not yetnot yetnot yet
September 29, 2026September 25, 2026 MEDP Sale $1,589,941 not yetnot yetnot yet
September 25, 2026September 23, 2026 MEDP Sale $27,403,895 not yetnot yetnot yet
September 23, 2026September 21, 2026 MEDP Sale $44,428,151 not yetnot yetnot yet
September 21, 2026September 17, 2026 MEDP Sale $6,749,952 not yetnot yetnot yet
September 17, 2026September 15, 2026 MEDP Sale $15,364,149 not yetnot yetnot yet
August 31, 2026August 27, 2026 MEDP Sale $403,176 not yetnot yetnot yet
August 27, 2026August 25, 2026 MEDP Sale $2,897,636 not yetnot yetnot yet
August 25, 2026August 21, 2026 MEDP Sale $9,969,094 not yetnot yetnot yet
August 21, 2026August 19, 2026 MEDP Sale $26,281,390 not yetnot yetnot yet
August 14, 2026August 12, 2026 MEDP Sale $7,111,969 not yetnot yetnot yet
August 12, 2026August 10, 2026 MEDP Sale $13,984,854 not yetnot yetnot yet
July 29, 2026July 27, 2026 MEDP Sale $4,346,004 +15.4%not yetnot yet
December 4, 2025December 3, 2025 MEDP Sale $394,581 −13.9%not yetnot yet
December 3, 2025December 1, 2025 MEDP Sale $17,114,847 −11.6%not yetnot yet
December 1, 2025November 26, 2025 MEDP Sale $34,074,470 −19.8%not yetnot yet
November 26, 2025November 24, 2025 MEDP Sale $61,967,338 −21.3%not yetnot yet
November 24, 2025November 20, 2025 MEDP Sale $17,031,557 −28.1%not yetnot yet
November 20, 2025November 18, 2025 MEDP Sale $18,376,705 −31.5%not yetnot yet
November 18, 2025November 14, 2025 MEDP Sale $12,352,076 −28.1%not yetnot yet
November 14, 2025November 12, 2025 MEDP Sale $6,288,183 −26.9%not yetnot yet
September 3, 2025August 29, 2025 MEDP Sale $17,794,383 +13.9%+2.6%+3.2%
August 28, 2025August 27, 2025 MEDP Sale $294,500 +18.4%+3.2%+6.6%
July 29, 2025July 28, 2025 MEDP Sale $21,901,093 +24.0%+12.8%+13.3%
May 29, 2024May 24, 2024 MEDP Sale $3,828,058 −12.3%−36.2%−36.8%
May 24, 2024May 22, 2024 MEDP Sale $22,000 −8.2%−37.2%−36.4%
May 22, 2024May 20, 2024 MEDP Sale $1,608,764 −7.1%−37.9%−37.6%
May 17, 2024May 15, 2024 MEDP Sale $15,924,222 −7.7%−37.6%−38.3%
May 14, 2024May 10, 2024 MEDP Sale $1,996,723 −10.0%−38.3%−39.5%
May 10, 2024May 8, 2024 MEDP Sale $3,310,566 −5.7%−38.6%−33.2%
May 8, 2024May 6, 2024 MEDP Sale $21,129,347 −5.9%−36.6%−35.7%
May 3, 2024May 1, 2024 MEDP Sale $6,553,671 −6.6%−35.7%−38.5%
May 1, 2024April 29, 2024 MEDP Sale $6,782,987 −9.5%−38.2%−35.4%
March 8, 2024March 6, 2024 MEDP Sale $82,321,250 −4.5%−30.4%−29.1%
March 6, 2024March 4, 2024 MEDP Sale $40,291,000 −5.8%−29.8%−32.3%
March 4, 2024February 29, 2024 MEDP Sale $40,024,600 −6.9%−32.5%−33.4%
February 29, 2024February 27, 2024 MEDP Sale $40,300,500 −7.6%−33.9%−37.6%
February 27, 2024February 23, 2024 MEDP Sale $62,938,689 −8.0%−37.6%−34.1%
February 23, 2024February 21, 2024 MEDP Sale $53,406,441 −8.1%−36.2%−32.5%
February 21, 2024February 16, 2024 MEDP Sale $24,992,323 −5.7%−32.0%−35.7%
December 1, 2023November 29, 2023 MEDP Sale $14,507,101 +34.7%−11.0%−9.1%
November 29, 2023November 27, 2023 MEDP Sale $12,877,319 +35.9%−7.6%−12.5%
November 27, 2023November 22, 2023 MEDP Sale $6,945,250 +34.8%−8.1%−10.7%
November 22, 2023November 21, 2023 MEDP Sale $6,934,250 +33.9%−11.1%−9.0%
November 21, 2023November 17, 2023 MEDP Sale $27,468,000 +34.0%−10.7%−17.8%
November 16, 2023November 14, 2023 MEDP Sale $21,217,980 +30.3%−17.8%−15.3%
September 23, 2022September 22, 2022 MEDP Purchase $8,877,485 +38.4%+49.1%+40.7%
September 22, 2022September 20, 2022 MEDP Purchase $29,814,076 +41.4%+49.0%+40.6%
September 20, 2022September 16, 2022 MEDP Purchase $23,796,527 +29.5%+39.9%+52.9%
September 16, 2022September 14, 2022 MEDP Purchase $19,115,517 +33.7%+49.5%+72.7%
September 14, 2022September 12, 2022 MEDP Purchase $20,298,778 +36.2%+64.3%+57.1%
September 12, 2022September 8, 2022 MEDP Purchase $18,210,223 +36.3%+66.7%+63.1%
September 8, 2022September 6, 2022 MEDP Purchase $16,871,519 +30.8%+59.9%+71.5%
September 6, 2022September 1, 2022 MEDP Purchase $13,143,379 +33.4%+63.0%+64.5%
July 20, 2022July 18, 2022 MEDP Purchase $1,207,850 +3.2%+35.1%+49.5%
July 18, 2022July 14, 2022 MEDP Purchase $3,222,911 +9.5%+42.4%+45.9%
June 16, 2015June 12, 2015 CHRS Sale $6,670,750 +2.5%−41.8%−39.3%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Troendle August J. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.